265 related articles for article (PubMed ID: 16778093)
1. Targeting the c-Met signaling pathway in cancer.
Peruzzi B; Bottaro DP
Clin Cancer Res; 2006 Jun; 12(12):3657-60. PubMed ID: 16778093
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
3. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
4. Targeting the HGF/Met signalling pathway in cancer.
Cecchi F; Rabe DC; Bottaro DP
Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
[TBL] [Abstract][Full Text] [Related]
5. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
Cui JJ
J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
[TBL] [Abstract][Full Text] [Related]
6. Host-pathogen systems biology: logical modelling of hepatocyte growth factor and Helicobacter pylori induced c-Met signal transduction.
Franke R; Müller M; Wundrack N; Gilles ED; Klamt S; Kähne T; Naumann M
BMC Syst Biol; 2008 Jan; 2():4. PubMed ID: 18194572
[TBL] [Abstract][Full Text] [Related]
7. Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F; Rabe DC; Bottaro DP
Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
[TBL] [Abstract][Full Text] [Related]
8. Progress in cancer therapy targeting c-Met signaling pathway.
Jung KH; Park BH; Hong SS
Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
[TBL] [Abstract][Full Text] [Related]
9. Molecular characteristics of HGF-SF and its role in cell motility and invasion.
Weidner KM; Hartmann G; Naldini L; Comoglio PM; Sachs M; Fonatsch C; Rieder H; Birchmeier W
EXS; 1993; 65():311-28. PubMed ID: 8380739
[TBL] [Abstract][Full Text] [Related]
10. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
[TBL] [Abstract][Full Text] [Related]
11. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
12. c-Met ectodomain shedding rate correlates with malignant potential.
Athauda G; Giubellino A; Coleman JA; Horak C; Steeg PS; Lee MJ; Trepel J; Wimberly J; Sun J; Coxon A; Burgess TL; Bottaro DP
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4154-62. PubMed ID: 16857786
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
14. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
15. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
Lancet Oncol; 2009 Jul; 10(7):709-17. PubMed ID: 19573800
[TBL] [Abstract][Full Text] [Related]
16. [A simple view on lung cancer biology: the MET pathway].
Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
[TBL] [Abstract][Full Text] [Related]
17. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
Tuck AB; Hota C; Wilson SM; Chambers AF
Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946
[TBL] [Abstract][Full Text] [Related]
19. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Xu H; Washington S; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
[TBL] [Abstract][Full Text] [Related]
20. Small molecule c-Met kinase inhibitors: a review of recent patents.
Porter J
Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]